|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||40.95 - 41.23|
|52 Week Range||33.38 - 43.95|
|PE Ratio (TTM)||32.76|
|Dividend & Yield||0.72 (1.74%)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis L’Oréal SA reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of L’Oréal SA – Procter & Gamble Company, Revlon, Inc. Class A, Avon Products, Inc., Inter Parfums, Inc., Unilever PLC Sponsored ADR, Sally Beauty Holdings, Inc. and Sanofi Sponsored ADR ... Read more (Read more...)
There are tons of reason to be skeptical about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock ahead of its second-quarter fiscal 2017 earnings results before Tuesday’s opening bell. The embattled drugmaker continues to make operational improvements, including divesting various non-core assets to lower debts. Since falling to a 52-week low of $8.31 on April 24, Valeant stock has skyrocketed as much as 118%, reaching $18.17 on July 25.
It's a beautiful thing, and a beautiful time to buy.